This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.

Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report) and keeping the price ...

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s ...

Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...

Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping ...

Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.

The next wave could grow the market further. Medtronic has received Food and Drug Administration approval to study its Affera ...

Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...